Cisplatin, etoposide and continuous infusion bleomycin in patients with testicular germ cell tumors: efficacy and toxicity data from a retrospective study

We retrospectively reviewed medical charts of 54 patients who underwent orchidectomy for germ cell tumors (GCT) and received a regimen, given every 3 weeks, consisting of cisplatin 100 mg/m2 day 4 intravenous (i.v.), bleomycin 15 Units (U) day 1 i.v. push; bleomycin 10 U days 1-3 24 h i.v. continuou...

Full description

Saved in:
Bibliographic Details
Published inJournal of chemotherapy (Florence) Vol. 21; no. 6; p. 687
Main Authors Curigliano, G, Spitaleri, G, Magni, E, Lorizzo, K, De Cobelli, O, Locatelli, M, Fumagalli, L, Adamoli, L, Cossu Rocca, M, Verri, E, De Pas, T, Jereczek-Fossa, B, Martinelli, G, Goldhirsch, A, Nolè, F
Format Journal Article
LanguageEnglish
Published England 01.12.2009
Subjects
Online AccessGet more information

Cover

Loading…
More Information
Summary:We retrospectively reviewed medical charts of 54 patients who underwent orchidectomy for germ cell tumors (GCT) and received a regimen, given every 3 weeks, consisting of cisplatin 100 mg/m2 day 4 intravenous (i.v.), bleomycin 15 Units (U) day 1 i.v. push; bleomycin 10 U days 1-3 24 h i.v. continuous infusion (c.i.) and etoposide 100 mg/m2 days 1-5/i.v. (PEB). 53 of 54 patients achieved a complete remission without adjunctive surgery. At a median follow-up of 48.2 months (95%CI 41.7 - 54.8 months) all patients but one are alive with no evidence of disease recurrence. Patients receiving PEB experienced no pulmonary toxicity, nephrotoxicity nor neurological adverse events. PEB with c.i.bleomycin is an active regimen with a low rate of acute and late toxicity. The main limitations of our study are related to the retrospective analysis, the limited number of patients and the restricted follow-up time. A prolonged follow-up is necessary to evaluate long term toxicity and outcome.
ISSN:1973-9478
DOI:10.1179/joc.2009.21.6.687